Coronary Artery Disease Integrated Polygenic Risk Score™
What is our iPRS™ for Coronary Artery Disease (CAD) test?
This test combines genetics, standard clinical factors, and lifestyle to provide a person's absolute risk of developing CAD within the next 10 years. This comprehensive assessment is more accurate than using clinical factors alone, helping to guide personalized treatments and screening recommendations. This test has been validated across multiple ancestries that are often inaccurately assessed with traditional clinical factors.
Comprehensive CAD Risk Assessment with iPRS
Comprehensive Analysis
Approximately 50% of CAD risk is due to heritable factors, many of which can be detected as genetic markers by the iPRS test.1
Clinical Risk Undetected
Up to 25% of cardiac events happen in individuals with no clinical risk factors.2
Reliable Risk Stratification
Nearly 10% of patients with uncertain* 10-year risk of CAD (as determined by traditional methods) were reclassified as high-risk by iPRS. Those patients had 3-fold higher risk of CAD incidence over 10 years.2
Clinical risk factor analysis includes
- Age
- Sex
- Race
- Blood Pressure
- Cholesterol levels
- Diabetes status
- Smoking status
- Hypertension treatment
Who is this test for?
The CAD iPRS test is intended for individuals aged 40-78 with no personal history of coronary artery disease who want to understand their risk of developing CAD. By providing a personalized risk assessment, the test empowers individuals to make informed, personalized decisions about their heart health to help prevent or delay the onset of disease.
Test Code
PR41003
(CAD iPRS, Proactive Health Plus)
PR42104
(CAD iPRS, Proactive Health)
Turn Around Times
From samples received, most results are delivered in 5 to 6 weeks*.
If you've already had MyOme testing performed, follow-up testing or re-requisitions are typically completed in under 2 weeks, often within just a few days.
Acceptable Sample Types
- Blood
- Buccal
- Saliva
Order a CAD iPRS test
We make it easy to order a CAD iPRS test to get insights for personalized care decisions.
This test can be ordered as part of the MyOme Proactive Health or MyOme Proactive Health Plus offerings depending on your needs. In addition, it can be ordered by itself.
Proactive Health Plus leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions.
Proactive Health uses blended genome-exome sequencing—offering a cost-effective option for preventative health decisions.
Interpreting CAD iPRS results
Guidelines support the use of medications, such as statins, to help reduce the risk of cardiovascular disease based on an individual's 10-year ASCVD risk estimation.1 At higher risk levels, medications and management of related conditions like hypertension and diabetes are recommended to lower risk. In addition, imaging may be advantageous to further refine risk assessment and should be discussed as part of a personalized risk management plan.
- Arnett, Donna K., et al. "2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Journal of the American College of cardiology 74.10 (2019): e177-e232.
Important considerations
The CAD iPRS test is a screening tool, not a diagnostic test. It does not detect high-risk monogenic variants like those for familial hypercholesterolemia (FH). Some with high scores won't develop CAD, while some with low scores will. Providers should consider personal and family history when assessing genetic testing needs. Genetic counseling or specialist consultation may aid further evaluation.
Get more information on how to order a MyOme test and get the process started.
Learn more about CAD iPRS
